Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19417541 | ACACIA NILOTICA BASED HYDROGEL AND METHOD OF MAKING THE SAME | December 2025 | February 2026 | Allow | 2 | 0 | 0 | No | No |
| 19347136 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | October 2025 | March 2026 | Allow | 5 | 1 | 1 | Yes | No |
| 19345445 | METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY | September 2025 | January 2026 | Allow | 3 | 1 | 0 | Yes | No |
| 19328055 | PREVENTION OF DISULFIDE BOND REDUCTION DURING RECOMBINANT PRODUCTION OF POLYPEPTIDES | September 2025 | December 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19324396 | MARINE ORGANISM DERIVED SURFACTANT | September 2025 | February 2026 | Allow | 5 | 0 | 1 | No | No |
| 19310812 | REVERSE TRANSCRIPTASE VARIANTS | August 2025 | November 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19309246 | BACTERIOPHAGE COMPOSITIONS FOR TREATING STAPHYLOCOCCUS INFECTION | August 2025 | March 2026 | Allow | 7 | 0 | 1 | Yes | No |
| 19308016 | NOVEL COMPOUNDS | August 2025 | October 2025 | Allow | 2 | 0 | 0 | No | No |
| 19280968 | COMBINATION OF NON-VIABLE CELLS OF STREPTOCOCCUS PYOGENES AND IMMUNE CHECKPOINT INHIBITOR FOR THE TREATMENT OF TRIPLE NEGATIVE BREAST CANCER AND NON-MUSCLE INVASIVE BLADDER CANCER | July 2025 | October 2025 | Allow | 3 | 0 | 0 | No | No |
| 19277384 | HERBAL ORAL COMPOSITIONS HAVING THE PROPERTIES FOR SUPPORTING AND ENHANCING MUSCULOSKELETAL HEALTH AND METHOD OF MANUFACTURING THE SAME | July 2025 | November 2025 | Allow | 4 | 1 | 0 | No | No |
| 19275921 | PLANT-BASED EXTRACT COMPLEX COMPOSITION HAVING THE PROPERTIES FOR SUPPORTING THE RELIEF OF MUSCULOSKELETAL PAIN, ANTIBACTERIAL AND ANTI-INFLAMMATORY AND PROCESS OF MANUFACTURING THE SAME | July 2025 | November 2025 | Allow | 4 | 1 | 1 | No | No |
| 19273915 | ENGINEERED MEGANUCLEASES HAVING SPECIFICITY FOR A RECOGNITION SEQUENCE IN THE HEPATITIS B VIRUS GENOME | July 2025 | March 2026 | Abandon | 8 | 1 | 0 | No | No |
| 19273324 | METHOD OF FACILITATING MITIGATION OF COSMETIC IMPERFECTIONS ASSOCIATED WITH FINGERPRINT IMPRESSIONS ON ANODIZED MATERIALS AND ANODIZED MATERIALS TREATED FOR PROVIDING SAME | July 2025 | September 2025 | Allow | 2 | 2 | 0 | No | No |
| 19269552 | CELLS, TISSUES, ORGANS, AND ANIMALS HAVING ONE OR MORE MODIFIED GENES FOR ENHANCED XENOGRAFT SURVIVAL AND TOLERANCE | July 2025 | November 2025 | Allow | 4 | 0 | 1 | No | No |
| 19254402 | Zonal and Targeted Methods and Uses for Treating a Chronic Post-Traumatic Headache Associated with a Post-Traumatic Stress Disorder | June 2025 | October 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19253325 | YEAST STAGE TANK INCORPORATED FERMENTATION SYSTEM AND METHOD | June 2025 | February 2026 | Allow | 8 | 1 | 1 | No | No |
| 19252680 | LIQUID DISPENSING SYSTEM, COMPONENTS AND FEATURES THEREOF, AND METHODS OF USE THEREOF | June 2025 | March 2026 | Allow | 8 | 1 | 1 | No | No |
| 19247982 | APPARATUS FOR TISSUE TRANSPORT AND PRESERVATION | June 2025 | March 2026 | Allow | 8 | 1 | 1 | No | No |
| 19245319 | FOOD COMPOSITION FOR REDUCING ALCOHOLIC HANGUP CONTAINING PLANT EXTRACT | June 2025 | August 2025 | Allow | 2 | 0 | 0 | No | No |
| 19242226 | Hyaluronidase Enzyme Formulations for High Volume Administration | June 2025 | January 2026 | Allow | 7 | 1 | 1 | No | No |
| 19242278 | CLINICAL DRESSING LOADED WITH COFFEE EXTRACT | June 2025 | January 2026 | Allow | 7 | 1 | 0 | No | No |
| 19241614 | CLINICAL DRESSING LOADED WITH COFFEE EXTRACT | June 2025 | February 2026 | Allow | 8 | 1 | 0 | No | No |
| 19237449 | RAPID ISOLATION, CULTIVATION METHODS AND UTILITIES OF TRUFFLE FUNGI | June 2025 | December 2025 | Allow | 6 | 2 | 1 | Yes | No |
| 19235902 | VASCULAR EMBOLIC SYSTEM | June 2025 | February 2026 | Allow | 8 | 1 | 0 | No | No |
| 19228731 | ENTERAL SUSTAINED-RELEASE SUGAR ALCOHOL ADDITIVE AND PREPARATION METHOD AND APPLICATION THEREOF | June 2025 | November 2025 | Allow | 5 | 1 | 0 | No | No |
| 19219183 | DESMOPRESSIN ORAL COMPOSITIONS | May 2025 | November 2025 | Allow | 6 | 1 | 0 | No | No |
| 19217808 | METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY | May 2025 | March 2026 | Allow | 9 | 2 | 1 | Yes | No |
| 19212294 | STABILIZATION OF TRYPTAMINES BY DENATURING ENZYMES, OPTIMIZING IONIZATION STATES, AND CONTROLLING CONFOUNDING VARIABLES | May 2025 | October 2025 | Allow | 5 | 1 | 1 | No | No |
| 19212289 | STABILIZATION OF TRYPTAMINES BY DENATURING ENZYMES, OPTIMIZING IONIZATION STATES, AND CONTROLLING CONFOUNDING VARIABLES | May 2025 | August 2025 | Allow | 3 | 0 | 1 | Yes | No |
| 19208663 | ANTIHYPERTENSIVE PEPTIDE PROBIOTIC GOAT MILK POWDER AND PREPARATION METHOD THEREOF | May 2025 | December 2025 | Allow | 7 | 2 | 1 | No | No |
| 19207422 | ASPERGILLUS FUMIGATUS FOR DEGRADING SOIL MICROPLASTICS AND APPLICATION THEREOF | May 2025 | December 2025 | Allow | 7 | 2 | 0 | No | No |
| 19206261 | PROCESS FOR CREATING A CANNABINOID PICO-EMULSION WITH ANTIBIOTIC PROPERTIES AND THE RESULTING PICO-EMULSION | May 2025 | February 2026 | Allow | 9 | 1 | 2 | No | No |
| 19207094 | LEPTIN COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME TO SUPPORT WEIGHT LOSS AND/OR MAINTENANCE | May 2025 | September 2025 | Allow | 5 | 1 | 1 | No | No |
| 19205571 | METHODS TO PRODUCE PRODUCTS COMPRISING CANNABINOIDS | May 2025 | August 2025 | Allow | 3 | 0 | 0 | No | No |
| 19205709 | Vaporized Medicants and Methods of Use | May 2025 | January 2026 | Abandon | 8 | 1 | 0 | No | No |
| 19205994 | SYSTEM FOR INDUCING MUTATION BASED ON OPTIMIZED ACTIVATION-INDUCED CYTIDINE DEAMINASE | May 2025 | December 2025 | Allow | 7 | 1 | 0 | No | No |
| 19205490 | TREATMENT OF FISTULA WITH BONE MARROW MESENCHYMAL STEM CELL DERIVED EXTRACELLULAR VESICLES | May 2025 | November 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19199523 | KITS FOR PREPARING AND DELIVERING PURIFIED CORTICOTROPIN | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19200045 | METHOD TO PREVENT AND TREAT DIABETIC RETINOPATHY BY CALCIUM CHANNEL BLOCKERS, ANGIOTENSIN CONVERTING ENZYME INHIBITORS, AND ANGIOTENSIN RECEPTOR BLOCKERS | May 2025 | March 2026 | Abandon | 10 | 1 | 0 | No | No |
| 19197254 | Vaccines against Chlamydia sp. | May 2025 | March 2026 | Allow | 10 | 2 | 1 | Yes | No |
| 19193303 | Skin Care Compositions and Methods of Using the Same | April 2025 | September 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 19192339 | ANTIMICROBIAL PEPTIDE AND APPLICATION THEREOF | April 2025 | February 2026 | Abandon | 10 | 0 | 1 | No | No |
| 19190359 | ANTIMICROBIAL COMPOSITIONS AND METHODS FOR MAKING AND USING THE SAME | April 2025 | November 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19186618 | GERMACRENE SYNTHASE SgTPS7 PROTEIN, CODING GENE AND USE IN SYNTHESIS OF GERMACRENE | April 2025 | November 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19187591 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | April 2025 | January 2026 | Allow | 9 | 1 | 1 | No | No |
| 19187241 | STORAGE STABLE FORMULATIONS OF SULFATED GLYCOSAMINOGLYCANS AND FRAGMENTS DERIVED THEREFROM FOR THE TREATMENT OF PAIN AND OTHER MEDICAL CONDITIONS | April 2025 | January 2026 | Allow | 9 | 2 | 0 | No | No |
| 19186223 | METHODS FOR MAKING L-GLUFOSINATE | April 2025 | August 2025 | Allow | 4 | 1 | 0 | No | No |
| 19184659 | LIPID-ENCAPSULATED DUAL-CLEAVING ENDONUCLEASE FOR DNA AND GENE EDITING | April 2025 | September 2025 | Allow | 5 | 1 | 0 | No | No |
| 19183815 | COMPOSITIONS AND METHODS OF ACHIEVING PAIN RELIEF | April 2025 | June 2025 | Allow | 1 | 0 | 1 | Yes | No |
| 19183742 | ALBUMIN RICH PEA PROTEIN ISOLATE AND PROCESS FOR PRODUCTION THEREOF | April 2025 | September 2025 | Allow | 5 | 0 | 1 | No | No |
| 19174121 | SEMAGLUTIDE IN MEDICAL THERAPY | April 2025 | December 2025 | Allow | 8 | 2 | 0 | No | No |
| 19173657 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | April 2025 | August 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19173652 | EUGLOBULIN-BASED METHOD FOR DETERMINING THE BIOLOGICAL ACTIVITY OF DEFIBROTIDE | April 2025 | December 2025 | Allow | 8 | 2 | 0 | Yes | No |
| 19173198 | INTERLEUKIN-15 SUPERAGONIST N-803 IN PEOPLE EXPERIENCING LONG COVID | April 2025 | February 2026 | Abandon | 10 | 1 | 0 | Yes | No |
| 19172886 | PAM3CSK4 INJECTION FOR THE PREVENTION AND MANAGEMENT OF MASLD | April 2025 | October 2025 | Allow | 6 | 0 | 1 | Yes | No |
| 19098553 | METHOD OF USING A GIP/GLP1 CO-AGONIST FOR DIABETES | April 2025 | August 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19096765 | ENDOPHYTIC FUNGUS OF OPHIOPOGON JAPONICUS AND USE THEREOF | April 2025 | September 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 19095861 | COMPOSITIONS, KITS, AND METHODS FOR IN VITRO TRANSCRIPTION | March 2025 | October 2025 | Allow | 7 | 0 | 1 | Yes | No |
| 19091737 | METHODS AND CHEMICAL COMPOSITIONS FOR TREATING SKIN CONDITIONS BY PROVIDING LONG LASTING SKIN PH CONTROL FOR IMPROVING SKIN BARRIER FUNCTION | March 2025 | July 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19089650 | ELECTROPORATION-TARGETED DELIVERY OF RIBOSOME INACTIVATING PROTEIN GELONIN INTO MAMMALIAN CELLS | March 2025 | October 2025 | Allow | 6 | 1 | 0 | No | No |
| 19085432 | COLLAGEN PEPTIDE-BASED MEDICAMENT COMPOSITIONS AND DEVICES AND METHODS OF PRODUCTION AND USE THEREOF | March 2025 | October 2025 | Allow | 7 | 1 | 0 | Yes | No |
| 19082426 | SENESCENCE INHIBITOR | March 2025 | January 2026 | Allow | 10 | 2 | 0 | No | No |
| 19081211 | FUSION PROTEINS COMPRISING ACID ALPHA-GLUCOSIDASE ENZYMES AND METHODS THEREOF | March 2025 | June 2025 | Allow | 3 | 0 | 0 | Yes | No |
| 19074055 | POLYNUCLEOTIDES ENCODING APOA-1 FUSION POLYPEPTIDES | March 2025 | September 2025 | Allow | 6 | 1 | 0 | No | No |
| 19071109 | COMPOSITIONS OF GLP-1 PEPTIDES AND PREPARATION THEREOF | March 2025 | December 2025 | Allow | 9 | 2 | 0 | No | No |
| 19070846 | Compositions and Methods for Treating Neurodegenerative Diseases and Disorders | March 2025 | January 2026 | Abandon | 11 | 2 | 0 | No | No |
| 19070810 | Compositions and Methods for Treating Cardiovascular Diseases and Disorders | March 2025 | February 2026 | Abandon | 11 | 2 | 0 | No | No |
| 19071345 | PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF | March 2025 | October 2025 | Allow | 8 | 1 | 0 | Yes | No |
| 19069812 | METHODS TO GENERATE POLYMER SCAFFOLDS HAVING A GRADIENT OF CROSSLINKING DENSITY | March 2025 | February 2026 | Allow | 11 | 1 | 1 | Yes | No |
| 19064774 | COMPOSITION AND METHOD FOR INDUCING NATURAL CONCEPTION | February 2025 | August 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19066076 | METHOD FOR PRODUCING A PLANT-BASED EXTRACT COMPOSITION HAVING THE EFFECT OF ENHANCING NUTRITION AND IMMUNITY | February 2025 | June 2025 | Allow | 4 | 1 | 1 | Yes | No |
| 18831490 | PREBIOTIC AND PROBIOTIC FORMULATION CONTAINING ACID AND HEAT RESISTANT BACTERIA | February 2025 | March 2026 | Abandon | 13 | 1 | 0 | No | No |
| 19059018 | Zonal and Targeted Methods and Uses for Treating a Post-Traumatic Stress Disorder | February 2025 | June 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 19055164 | Treatment for Chronic Kidney Disease | February 2025 | October 2025 | Abandon | 8 | 1 | 0 | No | No |
| 19054696 | DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS | February 2025 | September 2025 | Allow | 7 | 2 | 0 | Yes | No |
| 19052262 | Insulin Derivative | February 2025 | December 2025 | Abandon | 10 | 0 | 1 | No | No |
| 19048328 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN | February 2025 | December 2025 | Abandon | 10 | 1 | 0 | No | No |
| 19048080 | NOVEL RECOMBINANT FACTOR C AND METHOD FOR PRODUCING THE SAME, AND METHOD FOR MEASURING ENDOTOXIN | February 2025 | January 2026 | Abandon | 11 | 2 | 0 | No | No |
| 19044943 | INSECT NEUROPEPTIDES 8 | February 2025 | October 2025 | Allow | 8 | 1 | 1 | No | No |
| 19042887 | GIP/GLP1 AGONIST COMPOSITIONS | January 2025 | May 2025 | Allow | 4 | 0 | 0 | Yes | No |
| 18998009 | METHODS OF USING SYNTROPHUS ACIDITROPHICUS TO PRODUCE CYCLOHEXANE-1-CARBOXYLATE (CHC) | January 2025 | March 2026 | Allow | 14 | 0 | 1 | Yes | No |
| 19032240 | METHOD FOR PREPARING THEAFLAVIN WITH IMMOBILIZED SUBSTRATE | January 2025 | October 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 19028618 | SELECTIVE OXIDATION OF 5-METHYLCYTOSINE BY TET-FAMILY PROTEINS | January 2025 | July 2025 | Allow | 6 | 1 | 0 | Yes | No |
| 19028581 | COMPOSITE BACTERIAL AGENT AND APPLICATION THEREOF | January 2025 | February 2026 | Abandon | 13 | 2 | 0 | No | No |
| 19027003 | DIOXYGENASE MUTANTS AND USE THEREOF IN SYNTHESIZING (2S,3R)-3-HYDROXYPIPECOLIC ACID | January 2025 | August 2025 | Allow | 7 | 1 | 1 | Yes | No |
| 19026516 | ERGOTHIONEINE-PRODUCING ENGINEERED BACTERIA AND CONSTRUCTION METHOD AND USE THEREOF | January 2025 | October 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19023930 | GRAIN FRACTIONATION PROCESS | January 2025 | October 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19024178 | FACTOR IX POLYPEPTIDE MUTANT, ITS USES AND A METHOD FOR ITS PRODUCTION | January 2025 | October 2025 | Abandon | 9 | 0 | 1 | No | No |
| 19021675 | LACTICASEIBACILLUS RHAMNOSUS AFY01 AND APPLICATION OF PRODUCT PREPARED FROM LACTICASEIBACILLUS RHAMNOSUS AFY01 IN INFLAMMATORY COLON CANCER | January 2025 | July 2025 | Allow | 6 | 1 | 0 | No | No |
| 19023048 | PHARMACEUTICAL COMPOSITIONS COMPRISING NOVEL CYCLIC PEPTIDES | January 2025 | April 2025 | Allow | 3 | 1 | 0 | Yes | No |
| 19019039 | MODIFIED PH129 POLYMERASE AND USES THEREOF | January 2025 | November 2025 | Allow | 10 | 1 | 0 | No | No |
| 18993517 | A PHARMACEUTICAL COMPOSITION PROVIDING MUCOLYTIC EFFECT | January 2025 | October 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 19014260 | PFU DNA POLYMERASE MUTANTS WITH REVERSE TRANSCRIPTASE ACTIVITY AND THEIR APPLICATIONS | January 2025 | October 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19012840 | POLYSACCHARIDE COMPOUND WITH A DEFINED MOLECULAR STRUCTURE THAT CAN ELIMINATE THE TOXIC SIDE EFFECTS OF CHEMOTHERAPY DRUGS | January 2025 | June 2025 | Allow | 5 | 0 | 1 | Yes | No |
| 18880346 | RECOMBINANT ORGANISM AND METHOD | December 2024 | February 2026 | Allow | 13 | 2 | 0 | No | No |
| 19005540 | PREPARATION AND APPLICATION OF HIGH-ACTIVITY AND HIGH-SAFETY CARDAMINE VIOLIFOLIA SELENOPROTEIN STANDARD SAMPLE | December 2024 | June 2025 | Allow | 5 | 1 | 0 | No | No |
| 19005623 | COMPOSITIONS COMPRISING PEMVIDUTIDE AND AN ACYLATED AMINO ACID | December 2024 | October 2025 | Allow | 9 | 1 | 1 | Yes | No |
| 19005323 | PREPARATION METHOD FOR BIOSYNTHESIS OF HUMAN BODY STRUCTURAL MATERIAL | December 2024 | December 2025 | Allow | 12 | 1 | 1 | Yes | No |
| 18879948 | NOVEL PHOSPHOENOLPYRUVATE CARBOXYLASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAME | December 2024 | June 2025 | Allow | 6 | 0 | 0 | Yes | No |
| 18879995 | NOVEL 5-DEHYDRO-2-DEOXYGLUCONOKINASE VARIANT AND METHOD FOR PRODUCING 5’-INOSINIC ACID USING SAME | December 2024 | May 2025 | Allow | 5 | 0 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for group 1650.
With a 32.5% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 23.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Group 1650 is part of Technology Center 1600. This group has examined 98,082 patent applications in our dataset, with an overall allowance rate of 58.1%. Applications typically reach final disposition in approximately 33 months.
Applications in Group 1650 receive an average of 1.87 office actions before reaching final disposition. The median prosecution time is 33 months.
This group-level data aggregates statistics across multiple art units. For more targeted prosecution strategies, review the individual art unit and examiner statistics within this group.
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.